225 related articles for article (PubMed ID: 11807298)
1. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.
Hengge UR; Borchard C; Esser S; Schröder M; Mirmohammadsadegh A; Goos M
AIDS; 2002 Jan; 16(2):151-60. PubMed ID: 11807298
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
[TBL] [Abstract][Full Text] [Related]
4. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
Powles T; Imami N; Nelson M; Gazzard BG; Bower M
AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
[TBL] [Abstract][Full Text] [Related]
5. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
[TBL] [Abstract][Full Text] [Related]
8. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Hazenberg MD; Stuart JW; Otto SA; Borleffs JC; Boucher CA; de Boer RJ; Miedema F; Hamann D
Blood; 2000 Jan; 95(1):249-55. PubMed ID: 10607709
[TBL] [Abstract][Full Text] [Related]
9. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
[TBL] [Abstract][Full Text] [Related]
11. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
[TBL] [Abstract][Full Text] [Related]
12. Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study.
Bart PA; Meuwly JY; Corpataux JM; Yerly S; Rizzardi P; Fleury S; Munoz M; Knabenhans C; Welbon C; Pantaleo G; Meylan PR
AIDS; 1999 Aug; 13(12):1503-9. PubMed ID: 10465074
[TBL] [Abstract][Full Text] [Related]
13. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
14. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
15. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
Martinon F; Michelet C; Peguillet I; Taoufik Y; Lefebvre P; Goujard C; Guillet JG; Delfraissy JF; Lantz O
AIDS; 1999 Feb; 13(2):185-94. PubMed ID: 10202824
[TBL] [Abstract][Full Text] [Related]
16. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
17. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.
Fleury S; Rizzardi GP; Chapuis A; Tambussi G; Knabenhans C; Simeoni E; Meuwly JY; Corpataux JM; Lazzarin A; Miedema F; Pantaleo G
Proc Natl Acad Sci U S A; 2000 May; 97(10):5393-8. PubMed ID: 10805798
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative.
Landay AL; Bethel J; Schnittman S
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):445-51. PubMed ID: 9546804
[TBL] [Abstract][Full Text] [Related]
19. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
[TBL] [Abstract][Full Text] [Related]
20. Changes in tonsillar tissue in early HIV-1 infection and during 3 years of antiretroviral therapy.
Voltersvik P; Dyrhol-Riise AM; Bostad L; Røsok BI; Olofsson J; Asjö B
APMIS; 2000; 108(7-8):539-50. PubMed ID: 11167551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
